Albumin binding and how it produces a long half-life posts 31–45

Narrowing post #30, because the general version has more than one answer.

The most useful reply I ever got about albumin binding was a request to state my units. It sounds like pedantry and it has saved me twice.

Accumulation at steady state: with a week-long half-life, steady-state concentration is reached around 4 to 5 half-lives (about 4 to 5 weeks). Before that, concentration is rising with each dose. The clinical implication: escalating before 4 weeks means escalating before steady state.

A modest claim, modestly supported.

Albumin binding: semaglutide binds albumin through a fatty side chain, which sequesters the free form and extends the half-life. Tirzepatide also has albumin binding (different mechanism) which extends its half-life compared to an unmodified peptide.

Worth one more sentence than it usually gets.

Post #32 and I disagree about the size of the effect, not about the direction.

Reporting rather than recommending, on albumin binding. What happened is above. Whether it should have is a different question and not one I am qualified to answer.

The arithmetic in post #34 is right; the assumption feeding it is the part to check.

One more thing on albumin binding that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the apparent contradiction disappears.

Answering the question post #32 raises rather than the one it answers.

A pharmacokinetic model fitted to trial data describes the population studied. Applying it to somebody outside the enrolled range is an extrapolation, and the model will not tell you it is.

That is the distinction I keep failing to hold on to. Written down now.

Subcutaneous absorption is the rate-limiting step for most of these compounds, which is why the apparent half-life is absorption-limited rather than elimination-limited.

That is a description of practice, not a recommendation of it.

Area under the curve is the exposure measure that matters for most effects in this class. Peak concentration matters more for tolerability.

Adding a source would improve this post and I do not have one to hand.

The failure mode on albumin binding is boring rather than dramatic. It is almost always the step everyone assumes was done correctly because it is too simple to get wrong.

The number people quote for albumin binding is a central estimate presented without its interval, and the interval is wide enough that the estimate is nearly uninformative on its own.

Terminal half-life estimated from a short sampling window underestimates the true value. That is a common source of discrepant figures between sources.

Coming back to post #41, because the follow-up matters more than the original answer.

On albumin binding, I would rather understate and be corrected upward than overstate and be quoted. That is a house style here and it is a good one.

Post #41 is right about the mechanism and I think understates the practical bit.

Reading this albumin binding thread as someone who came in with a fixed view: the third and seventh replies moved me and the confident ones did not.